Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Revenues $ 153 $ 75 $ 275 $ 210
Operating expenses:        
Research and development (related party of $197, $206, $373 and $445), net of grant income of $0, $4, $44 and $40 993 1,049 1,978 1,869
General and administrative (related party of $181, $187, $387 and $362) 2,587 2,351 5,085 4,820
Total operating expenses 3,580 3,400 7,063 6,689
Operating loss (3,427) (3,325) (6,788) (6,479)
Other income (expense):        
Interest expense (related party of $479, $483, $959 and $966) (479) (483) (959) (966)
Interest income 4 12 9 25
Royalty income 2 4 11 16
Total other income (expense) (473) (467) (939) (925)
Consolidated net loss (3,900) (3,792) (7,727) (7,404)
Net loss attributable to noncontrolling interest 1 563 2 1,114
Net loss attributable to iBio, Inc. (3,899) (3,229) (7,725) (6,290)
Preferred stock dividends (65) 0 (131) 0
Net loss available to iBio, Inc. (3,964) (3,229) (7,856) (6,290)
Comprehensive loss:        
Consolidated net loss (3,900) (3,792) (7,727) (7,404)
Other comprehensive income (loss) - foreign currency translation adjustments 0 0 0 0
Comprehensive loss $ (3,900) $ (3,792) $ (7,727) $ (7,404)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.04) $ (0.08) $ (0.07)
Weighted-average common shares outstanding - basic and diluted 96,609 89,109 96,127 89,109